|
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 994-996.
Prepublished online as a Blood First Edition Paper on October 19, 2004; DOI 10.1182/blood-2004-07-2965.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report
Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell–directed therapy
Michael C. Milone,
Donald E. Tsai,
Richard L. Hodinka,
Lewis B. Silverman,
Alejandro Malbran,
Mariusz A. Wasik, and
Kim E. Nichols
From the Department of Pathology and Laboratory Medicine and the Hematologic Malignancies Program, University of Pennsylvania; the Clinical Virology Laboratory and the Department of Pediatric Oncology, Children's Hospital of Philadelphia; the Departments of Pediatrics and Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA; the Department of Pediatric Oncology, Dana-Farber Cancer Institute; the Department of Pediatric Hematology-Oncology, Children's Hospital, Boston MA; and the Department of Allergy and Immunology, Hospital Britanico, Buenos Aires, Argentina.
X-linked lymphoproliferative disease (XLP) is a congenital immunodeficiency that is characterized by an abnormal immune response to primary Epstein-Barr virus (EBV) infection. After EBV exposure, affected patients often develop fulminant infectious mononucleosis (FIM), a life-threatening condition marked by the uncontrolled expansion and activation of T and B lymphocytes and macrophages. We hypothesized that the rapid elimination of B cells immediately following EBV exposure might reduce the severity of primary EBV infection in patients with XLP. To test this possibility, we administered the anti-CD20 antibody rituximab to 2 patients who presented with acute infection. Following treatment, both patients exhibited a complete resolution of symptoms and no longer demonstrated detectable EBV DNA within circulating lymphocytes. Moreover, neither patient has developed FIM or lymphoma in more than 2 years of follow-up. These data suggest that the pre-emptive use of B-cell–directed therapy may reduce the morbidity and mortality of primary EBV infection in XLP-affected individuals.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Pachlopnik Schmid, D. Moshous, N. Boddaert, B. Neven, L. Dal Cortivo, M. Tardieu, M. Cavazzana-Calvo, S. Blanche, G. de Saint Basile, and A. Fischer
Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients
Blood,
July 2, 2009;
114(1):
211 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mahlaoui, M. Ouachee-Chardin, G. de Saint Basile, B. Neven, C. Picard, S. Blanche, and A. Fischer
Immunotherapy of Familial Hemophagocytic Lymphohistiocytosis With Antithymocyte Globulins: A Single-Center Retrospective Report of 38 Patients
Pediatrics,
September 1, 2007;
120(3):
e622 - e628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mischler, G. M. Fleming, T. P. Shanley, L. Madden, J. Levine, V. Castle, A. H. Filipovich, and T. T. Cornell
Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis and X-Linked Lymphoproliferative Disease: A Mimicker of Sepsis in the Pediatric Intensive Care Unit
Pediatrics,
May 1, 2007;
119(5):
e1212 - e1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Lemas and R. F. Ambinder
The kiss that scars
Blood,
July 1, 2006;
108(1):
8 - 8.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Thaunat, M.-F. Mamzer-Bruneel, F. Agbalika, F. Valensi, M. Venditto, C. Lebbe, C. Frances, R. Kania, L. Chatenoud, C. Antoine, et al.
Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody.
Blood,
April 1, 2006;
107(7):
3009 - 3010.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Williams and D. H. Crawford
Epstein-Barr virus: the impact of scientific advances on clinical practice
Blood,
February 1, 2006;
107(3):
862 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
